Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes

Amulya Yellala, MBBS, Elizabeth R. Lyden, MS, Heather Nutsch, Avyakta Kallam, MD, Kai Fu, MD PhD, Timothy C. Greiner, MS, MD, Philip Bierman, MD, Matthew A. Lunning, DO, FACP, R. Gregory Bociek, MD, James O. Armitage, MD, Julie M. Vose, MD MBA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-142743

Published: 2020

Journal Articles

Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Matthew A. Lunning, DO, Philip Bierman, MD, R. Gregory Bociek, MD, Marshall T. Schreeder, MD, Tanya Siddiqi, MD, Christopher R Flowers, MD MS, Jonathon B. Cohen, MD MS, Susan Blumel, RN, Kathy Cutter, RN, Emily K. Pauli, BMBS,PharmD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S. Weiss, Julie M. Vose, MD MBA

Blood (2018) 132 (Supplement 1): 4197.

https://doi.org/10.1182/blood-2018-99-118917

Published: 2018

Journal Articles

A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Matthew A. Lunning, DO, Philip Bierman, MD, R. Gregory Bociek, MD, James O. Armitage, MD, Peggy Heires, R.N., Maribeth Hohenstein, R.N, Susan Blumel, RN, Jonathan Tefft, B.A., Elizabeth R. Lyden, MS, Michael R Green, PhD, Julie M. Vose, MD MBA

Blood (2018) 132 (Supplement 1): 5390.

https://doi.org/10.1182/blood-2018-99-119765

Published: 2018

Journal Articles

Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Avyakta Kallam, MBBS, Jane Meza, PhD, Philip Bierman, MD, Matthew A. Lunning, DO, R. Gregory Bociek, MD, James Olen Armitage, MD, Julie M Vose, MD

Blood (2017) 130 (Supplement 1): 4039.

https://doi.org/10.1182/blood.V130.Suppl_1.4039.4039

Published: 2017

Journal Articles

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

Andrew M Evens, DO,MSc, Ranjana H. Advani, MD, Michelle A. Fanale, MD, Sonali M. Smith, MD, Irene Helenowski, PhD, Borko Jovanovic, PhD, R. Gregory Bociek, MD, Andreas Klein, MD, Jane N. Winter, MD, Leo I. Gordon, MD, Paul A. Hamlin, MD

Blood (2017) 130 (Supplement 1): 733.

https://doi.org/10.1182/blood.V130.Suppl_1.733.733

Published: 2017

Journal Articles

Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

Matthew Lunning, DO, Philip J Bierman, MD, R. Gregory Bociek, MD, Marshall T. Schreeder, MD, Susan Blumel, RN, BSN, Kathy Cutter, RN, BSN, Emily K. Pauli, BMBS, PharmD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Julie M Vose, MD

Blood (2016) 128 (22): 4197.

https://doi.org/10.1182/blood.V128.22.4197.4197

Published: 2016

Journal Articles

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

Jayadev Manikkam Umakanthan, MBBS, Lori J. Maness, MD, Jiangtao Luo, Avyakta Kallam, MBBS, James O. Armitage, MD, Philip Bierman, MD, Julie M. Vose, MD, R. Gregory Bociek, MD, Matthew Lunning, DO, Krishna Gundabolu, MD, Vijaya R. Bhatt, MD

Blood (2016) 128 (22): 5154.

https://doi.org/10.1182/blood.V128.22.5154.5154

Published: 2016

Journal Articles

Use of Low Molecular Weight Heparin (LMWH) in Thrombocytopenic Patients with Hematologic Malignancy-Associated Venous Thromboembolism (VTE)

Nabin Khanal, MBBS, R. Gregory Bociek, MD, Baojiang Chen, PhD, Julie M. Vose, MD, James O. Armitage, MD, Philip J Bierman, MD, Lori J. Maness, MD, Matthew A. Lunning, DO, Krishna Gundabolu, MD, Vijaya R. Bhatt, MD

Blood (2015) 126 (23): 3482.

https://doi.org/10.1182/blood.V126.23.3482.3482

Published: 2015

Journal Articles

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

Anas Younes, MD, Gilles Salles, Giovanni Martinelli, R. Gregory Bociek, MD, Dolores Caballero Barrigon, MD, Eva Gonzalez Barca, Mehmet Turgut, MD PhD, John F. Gerecitano, MD, Fabian Herbst, Lisa Williams, Nabanita Mukherjee, Ranjana Tavorath, Won Seog Kim, MD PhD

Blood (2015) 126 (23): 1493.

https://doi.org/10.1182/blood.V126.23.1493.1493

Published: 2015

Journal Articles

Tolerability and Efficacy of Treatments in Elderly Patients with Hodgkin Lymphoma: A Report from the Nebraska Lymphoma Study Group

Roberto A. Ferro, MD, Vijaya R. Bhatt, MD, Martin Bast, BS, Lynette Smith, MS, R. Gregory Bociek, MD, Matthew A. Lunning, DO, Philip J Bierman, MD, Julie M. Vose, MD, James O. Armitage, MD

Blood (2015) 126 (23): 1504.

https://doi.org/10.1182/blood.V126.23.1504.1504

Published: 2015

Journal Articles

National Trend in Splenectomy for Splenic Marginal Zone Lymphoma (SMZL): An Analysis of Surveillance, Epidemiology and End Results (SEER) Database

Smith Giri, MBBS, Vijaya R. Bhatt, MD, Ranjan Pathak, MD, R. Gregory Bociek, MD, James O. Armitage, MD

Blood (2015) 126 (23): 5630.

https://doi.org/10.1182/blood.V126.23.5630.5630

Published: 2015

Journal Articles

Clinicopathologic Features, Management and Outcomes of Blastoid Variant (BV) of Mantle Cell Lymphoma (MCL): A Nebraska Lymphoma Study Group (NLSG) Experience

Vijaya R. Bhatt, MBBS, Fausto R. Loberiza, MD MS, James O. Armitage, MD, Timothy C. Greiner, MS, MD, Martin Bast, BS, Matthew A. Lunning, DO, Philip Bierman, MD, Julie M. Vose, MD MBA, R. Gregory Bociek, MD MSc.

Blood (2014) 124 (21): 2971.

https://doi.org/10.1182/blood.V124.21.2971.2971

Published: 2014

Journal Articles

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Ann LaCasce, MD, R. Gregory Bociek, MD, Jeffrey Matous, MD, Ahmed Sawas, MD, Paolo Caimi, MD, Stephen M. Ansell, MD PhD, Miguel Islas-Ohlmayer, MD, Eric Cheung, MD, Edward Agura, MD, Caroline Behler, MD, Howland Crosswell, MD, Julie M. Vose, MD MBA, Neil Josephson, MD, Ranjana Advani, MD

Blood (2014) 124 (21): 293.

https://doi.org/10.1182/blood.V124.21.293.293

Published: 2014

Journal Articles

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma

Anas Younes, Gilles Salles, MDPhD, R. Gregory Bociek, MD, Giovanni Martinelli, Dolores Caballero, Eva González Barca, Nabanita Mukherjee, Lisa Williams, Fabian Herbst, Ranjana Tavorath, Won Seog Kim

Blood (2014) 124 (21): 1718.

https://doi.org/10.1182/blood.V124.21.1718.1718

Published: 2014

Journal Articles

Trend Analysis of Clinical Outcomes in Hodgkin Lymphoma over the Last Three Decades: Report from the Nebraska Lymphoma Study Group

Kailash Mosalpuria, MD MPH, Fausto R Loberiza, MD MS, R. Gregory Bociek, MD, Matthew A. Lunning, DO, Apar Kishor Ganti, MD, James Olen Armitage, MD, Julie M. Vose, MD, Philip Bierman, MD

Blood (2014) 124 (21): 1284.

https://doi.org/10.1182/blood.V124.21.1284.1284

Published: 2014

Journal Articles

Restrospective Review of Incidence, Complications and Management of Tumor Lysis Syndrome in High Risk Patients with Hematologic Malignancies

Devon M Greer, PharmD, Jairam Krishnamurthy, MD, Susanne Liewer, PharmD, Mojtaba Akhtari, MD, Lori J. Maness, MD, R. Gregory Bociek, MD

Blood (2014) 124 (21): 2621.

https://doi.org/10.1182/blood.V124.21.2621.2621

Published: 2014

Journal Articles

Disparity In Clinical Outcomes Of Elderly Patients With Non-Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation According To Area Of Residence

Andrew C. Cannon, B.S., James Olen Armitage, MD, Philip Bierman, MD, R. Gregory Bociek, MD, Julie M. Vose, MD, Fausto R. Loberiza, Jr., MD, MS

Blood (2013) 122 (21): 1744.

https://doi.org/10.1182/blood.V122.21.1744.1744

Published: 2013

Journal Articles

Utility Of Pre-Chemotherapy Echocardiograms

John Allen Steuter, MD/Cardiology Fellow, Philip Bierman, MD, R. Gregory Bociek, MD, Martin Bast, BS

Blood (2013) 122 (21): 2950.

https://doi.org/10.1182/blood.V122.21.2950.2950

Published: 2013

Journal Articles

Cell Of Origin Does Not Affect Outcomes In Early Stage Non-Bulky Diffuse Large B-Cell Lymphoma Treated With Short-Course Combined Modality Therapy

Matthew A. Lunning, DO, Jocelyn C. Maragulia, BS, Anita Kumar, MD, Martin Bast, BS, Philip Bierman, MD, R. Gregory Bociek, MD, Julie M Vose, MD, MBA, James O. Armitage, MD, Steven M. Horwitz, MD, Andrew D Zelenetz, MD, PhD

Blood (2013) 122 (21): 3017.

https://doi.org/10.1182/blood.V122.21.3017.3017

Published: 2013

Journal Articles

CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

Craig H. Moskowitz, MD, Anas Younes, MD, Sven de Vos, MD, PhD, R. Gregory Bociek, MD, Leo I. Gordon, MD, Thomas E. Witzig, MD, Randy D. Gascoyne, MD, Brian West, Ph.D., Keith Nolop, MD, Christian Steidl, MD

Blood (2012) 120 (21): 1638.

https://doi.org/10.1182/blood.V120.21.1638.1638

Published: 2012

NARROW

Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes

Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

Combination of Ublituximab, TGR-1202, and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

Use of Low Molecular Weight Heparin (LMWH) in Thrombocytopenic Patients with Hematologic Malignancy-Associated Venous Thromboembolism (VTE)

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)

Tolerability and Efficacy of Treatments in Elderly Patients with Hodgkin Lymphoma: A Report from the Nebraska Lymphoma Study Group

National Trend in Splenectomy for Splenic Marginal Zone Lymphoma (SMZL): An Analysis of Surveillance, Epidemiology and End Results (SEER) Database

Clinicopathologic Features, Management and Outcomes of Blastoid Variant (BV) of Mantle Cell Lymphoma (MCL): A Nebraska Lymphoma Study Group (NLSG) Experience

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma

Trend Analysis of Clinical Outcomes in Hodgkin Lymphoma over the Last Three Decades: Report from the Nebraska Lymphoma Study Group

Restrospective Review of Incidence, Complications and Management of Tumor Lysis Syndrome in High Risk Patients with Hematologic Malignancies

Disparity In Clinical Outcomes Of Elderly Patients With Non-Hodgkin Lymphoma After Autologous Hematopoietic Stem Cell Transplantation According To Area Of Residence

Utility Of Pre-Chemotherapy Echocardiograms

Cell Of Origin Does Not Affect Outcomes In Early Stage Non-Bulky Diffuse Large B-Cell Lymphoma Treated With Short-Course Combined Modality Therapy

CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only